Viewing Study NCT02461134



Ignite Creation Date: 2024-05-06 @ 7:06 AM
Last Modification Date: 2024-10-26 @ 11:44 AM
Study NCT ID: NCT02461134
Status: TERMINATED
Last Update Posted: 2018-05-09
First Post: 2015-04-28

Brief Title: Clinical Study to Investigate the Biological Activity Safety Tolerability and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Sponsor: Actelion
Organization: Actelion

Study Overview

Official Title: A Phase 2 Open-label Single-arm Intra-subject Dose-escalation Study to Investigate the Biological Activity Safety Tolerability and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy
Status: TERMINATED
Status Verified Date: 2018-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Low recruitment
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Chronic graft versus host diseasre GVHD is a serious reaction that might occur in a person the host who has received cells or organs graft from another person because the graft attacks the hosts cells Currently there are no approved therapies for chronic GVHD in the USA and patients with chroninc GVHD are treated with immunosuppressant drugs T-lymphocytes a type of white blood cells are likely to play a role in the development of chronic GVHD Due to the capacity of ponesimod to block the traffic of T-lymphocytes ponesimod may be a new therapeutic approach to treat chroninc GVHD

The main objective of this study is to assess the effectiveness and safety of several doses of ponesimod in subjects with chronic GVHD who did not respond to standard available treatments
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None